Corticotropin ( DrugBank: Corticotropin )

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
13	多発性硬化症／視神経脊髄炎	3
46	悪性関節リウマチ	1
75	クッシング病	3
81	先天性副腎皮質酵素欠損症	2
84	サルコイドーシス	1
222	一次性ネフローゼ症候群	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01906658 (ClinicalTrials.gov)	July 2013	15/7/2013	A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis	A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Repository corticotropin injection	Mallinckrodt	NULL	Completed	18 Years	80 Years	All	43	Phase 2	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03126760 (ClinicalTrials.gov)	May 22, 2017	4/4/2017	Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	Relapsing, Remitting Multiple Sclerosis	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt	NULL	Terminated	18 Years	N/A	All	35	Phase 4	United States
2	NCT01888354 (ClinicalTrials.gov)	April 2013	16/5/2013	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Multiple Sclerosis (MS)	Drug: H.P. Acthar Gel (repository corticotropin injection)	The University of Texas Health Science Center, Houston	NULL	Completed	18 Years	55 Years	Both	25	Phase 4	United States
3	NCT00986960 (ClinicalTrials.gov)	December 2009	29/9/2009	Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)	Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study	Multiple Sclerosis	Drug: repository corticotropin injection;Drug: Saline	University at Buffalo	NULL	Terminated	18 Years	65 Years	All	3	Phase 2	United States

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01966718 (ClinicalTrials.gov)	October 2013	14/10/2013	Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.	Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action	Rheumatoid Arthritis	Drug: Repository corticotropin injection	Arthritis Treatment Center, Maryland	NULL	Completed	18 Years	80 Years	All	8	Phase 4	United States

75. クッシング病

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02468193 (ClinicalTrials.gov)	September 24, 2015	8/6/2015	Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome	A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease	Cushing's Syndrome;Ectopic Corticotropin Syndrome;Adrenal Adenoma;Adrenal Carcinoma;AIMAH;PPNAD	Drug: Osilodrostat	Novartis Pharmaceuticals	NULL	Completed	18 Years	85 Years	All	9	Phase 2	Japan
2	NCT01459237 (ClinicalTrials.gov)	October 11, 2011	21/10/2011	Effects of Hormone Stimulation on Brain Scans for Cushing s Disease	Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease	Pituitary Neoplasm	Drug: Acthrel	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	8 Years	N/A	All	30	Early Phase 1	United States
3	NCT00001180 (ClinicalTrials.gov)	March 1982	3/11/1999	Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency	Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency	Adrenal Gland Hyperfunction;Adrenal Gland Hypofunction;Cushing's Syndrome;Healthy	Drug: Ovine Corticotropin-Releasing Hormone (oCRH)	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	NULL	Completed	N/A	N/A	Both	2250	N/A	United States

81. 先天性副腎皮質酵素欠損症

臨床試験数 : 87 / 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004381-19-IT (EUCTR)	13/10/2021	30/08/2021	Study to Evaluate the Safety and Efficacy of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment - n/a	Congenital adrenal hyperplasia (CAH) is a group of rare inherited endocrine disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: Crinecerfont Product Code: [NBI-74788] Other descriptive name: Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist. Product Name: Crinecerfont Product Code: [NBI-74788] Other descriptive name: Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist.	Neurocrine Biosciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	81	Phase 3	France;United States;Greece;Canada;Spain;Poland;Belgium;Germany;Italy;Sweden
2	EUCTR2019-004873-17-IT (EUCTR)	16/12/2020	24/05/2021	A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment - n/a	Congenital adrenal hyperplasia (CAH) is a group of rare inherited endocrine disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. MedDRA version: 20.0;Level: LLT;Classification code 10010323;Term: Congenital adrenal hyperplasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: Crinecerfont Product Code: [NBI-74788] Other descriptive name: Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist.	Neurocrine Biosciences, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	165	Phase 3	Greece;Spain;Austria;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Bulgaria;Germany;Netherlands;Sweden;United States;Portugal;Czechia

84. サルコイドーシス

臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02920710 (ClinicalTrials.gov)	February 1, 2019	29/9/2016	ACTHAR Therapy for Central Nervous System Sarcoidosis	ACTHAR Therapy for Central Nervous System Sarcoidosis	Sarcoidosis	Drug: Repository Corticotropin Injection	The Cleveland Clinic	Mallinckrodt	Withdrawn	N/A	N/A	All	0	Phase 4	United States

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01386554 (ClinicalTrials.gov)	August 2011	29/6/2011	Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients	A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)	Proteinuria;Idiopathic Membranous Nephropathy	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt	NULL	Completed	18 Years	N/A	All	60	Phase 4	United States;Canada;Chile;Mexico;Turkey

先頭へ